Zerrin Kutlu | Molecular | Excellence in Research Award

Published on by Biotechnology Scientist

Assoc. Prof. Dr. Zerrin Kutlu | Molecular | Excellence in Research Award

Researcher at Ataturk University | Turkey

Assoc. Prof. Dr. Zerrin Kutlu is a distinguished biochemist whose research excellence is demonstrated through her impactful contributions to oxidative stress biology, endoplasmic reticulum stress, inflammation, metabolic disorders, and therapeutic drug discovery. With 211 citations across 198 documents, 15 publications, and a Scopus h-index of 9, she has established a credible scientific footprint in translational biochemistry and experimental pharmacology. Her research spans ischemic heart injury, diabetes-related complications, sepsis-induced organ damage, ferroptosis, and antioxidant-based cytoprotective strategies. She has extensively studied avasopasem manganese (a SOD mimetic), ER-stress modulators, nanoformulations for wound healing, and bioactive natural compounds with therapeutic potential. Her experimental work includes the elucidation of molecular pathways such as unfolded protein response mechanisms, inflammatory cascades, prostaglandin receptor signaling, and oxidative injury biomarkers. She has authored SCI/SCI-Expanded articles and contributed multiple book chapters reflecting her sustained scientific productivity. Her involvement in dermocosmetic innovation and boron-based bioactive molecule development illustrates strong translational impact. Her research outputs demonstrate originality, advanced methodology, and significant biomedical relevance, solidifying her suitability for the Excellence in Research Award.

Profiles : Scopus | ORCID | Google Scholar

Featured Publications

Dumlu, F. A., Aydin, T., Odabasoglu, F., Berktas, O. A., Kutlu, Z., Erol, H. S., … (2019). Anti-inflammatory and antioxidant properties of jervine, a steroidal alkaloid from rhizomes of Veratrum album. Phytomedicine, 55, 191–199. (Cited by: 46)

Koc, K., Geyikoglu, F., Cakmak, O., Koca, A., Kutlu, Z., Aysin, F., Yilmaz, A., … (2021). The targets of β-sitosterol as a novel therapeutic against cardio-renal complications in acute renal ischemia/reperfusion damage. Naunyn-Schmiedeberg’s Archives of Pharmacology, 394(3), 469–479. (Cited by: 44)

Karaoğlan, E. S., Albayrak, A., Kutlu, Z., & Bayır, Y. (2018). Gastroprotective and antioxidant effects of Eremurus spectabilis Bieb. methanol extract and its isolated component isoorientin on indomethacin-induced gastric ulcer. Acta Cirurgica Brasileira, 33, 609–618. (Cited by: 30)

Akpinar, E., Kutlu, Z., Kose, D., Aydin, P., Tavaci, T., Bayraktutan, Z., Yuksel, T. N., … (2022). Protective effects of idebenone against sepsis-induced acute lung damage. Journal of Investigative Surgery, 35(3), 560–568. (Cited by: 25)

Kutlu, Z., Celik, M., Bilen, A., Halıcı, Z., Yıldırım, S., Karabulut, S., Karakaya, S., … (2020). Effects of umbelliferone isolated from the Ferulago pauciradiata Boiss. & Heldr. plant on cecal ligation and puncture-induced sepsis model in rats. Biomedicine & Pharmacotherapy, 127, 110206. (Cited by: 21)

Ning Zhang | Molecular biotechnology | Best Researcher Award

Published on by Biotechnology Scientist

Assoc. Prof. Dr. Ning Zhang | Molecular Biotechnology | Best Researcher Award

Associate Professor at Liaocheng university | China

Assoc. Prof. Dr. Ning Zhang, a distinguished neuroscientist of Mongolian ethnicity, is a member of the Communist Party and currently focuses her research on neuroinflammatory immunity and myelin regeneration. She earned her doctoral degree in Neuroscience from Tierärztliche Hochschule Hannover, Germany, in November 2015. Dr. Zhang’s research primarily investigates the regulatory mechanisms of neuroinflammation and immune responses in neurodegenerative diseases, emphasizing the processes of remyelination and neuronal repair. Her studies further explore the intricate interactions among glial cells in the central nervous system during both development and disease progression. She is also deeply engaged in identifying novel therapeutic targets for neurodegenerative conditions and developing bioactive interventions aimed at mitigating neuronal damage. Dr. Zhang has made substantial contributions to the field through her publications and scientific discoveries, advancing understanding of cellular and molecular mechanisms underlying neural repair. Her work bridges fundamental neuroscience with translational approaches to improve clinical outcomes in neurodegenerative disorders. According to her Scopus profile, Dr. Zhang has authored 62 scientific documents, which have collectively garnered 868 citations across 667 publications, reflecting a significant impact in the global neuroscience community. She maintains an h-index of 19, demonstrating both the depth and influence of her research contributions in neuroinflammatory and regenerative neuroscience.

Profile: Scopus

Featured Publications

Zhang, N., et al. (2025). Ketogenic diet attenuates microglia-mediated neuroinflammation by inhibiting NLRP3 inflammasome activation via HDAC3 inhibition to activate mitophagy in experimental autoimmune encephalomyelitis. Food & Function. 3 citations

Zhang, N., et al. (2025). Exogenous ketogenic supplements can mitigate the susceptibility to Alzheimer’s disease induced by chronic sleep deprivation: Emerging role of Sirt1 in ferroptosis. Food Science and Human Wellness. 0 citations

Zhang, N., et al. (2025). Cetirizine platinum(IV) complexes with antihistamine properties inhibit tumor metastasis by suppressing angiogenesis and boosting immunity. Journal of Inorganic Biochemistry. 3 citations

Zhang, N., et al. (2024). Dynamic effects of ketogenic diet on autophagy and cell cycle in a mouse model of CT26+ colon cancer. Pakistan Journal of Zoology. 0 citations

Zhang, N., et al. (2024). Phase separation investigation of Axitinib in supersaturated solution. Crystals. 0 citations

Yu Fang | Molecular biotechnology | Best Researcher Award

Published on by Biotechnology Scientist

Prof. Dr. Yu Fang | Molecular biotechnology | Best Researcher Award

Full Professor at Fujian Institute of Research on the Structure of Matter | China

Dr. Yu Fang is a distinguished chemist whose research lies at the interface of materials chemistry and supramolecular science, particularly in the design and synthesis of Porous Coordination Cages (PCCs) and Metal–Organic Frameworks (MOFs). His work focuses on developing advanced porous materials for applications in catalysis, gas storage, molecular recognition, and energy conversion. Dr. Fang has made significant contributions to understanding host–guest chemistry, self-assembly mechanisms, and structure–property relationships in coordination materials. His innovative research has been widely recognized in leading journals such as Nature Communications, Angewandte Chemie International Edition, Journal of the American Chemical Society, and Chemical Society Reviews. Through collaborative projects and pioneering insights, Dr. Fang’s studies have bridged molecular design and functional materials engineering, influencing both academic and industrial research in advanced materials. He has published extensively, contributing to the development of next-generation coordination architectures with tailored porosity and dynamic behavior for chemical and environmental applications. With 7132 citations and an h-index of 26 according to his Scopus profile, Dr. Fang’s scientific impact reflects both productivity and quality, positioning him as a leading figure in coordination chemistry and materials innovation.

Profile: Google Scholar | Orcid

Featured Publications

Liang, Y., Yang, X., Wang, X., Guan, Z.-J., Xing, H., & Fang, Y. (2023). Nature Communications, 14, 5223.

Su, Z., Liu, K.-K., Xu, Y.-Q., Yan, B., Wang, S., Guan, Z.-J., Zou, Y., & Fang, Y. (2024). Angewandte Chemie International Edition, 64(9), e202420945.

Peng, Y., Yuan, L., Liu, K.-K., Jin, S., & Fang, Y. (2024). Angewandte Chemie International Edition, 64(12), e202423055.

Liang, Y., Xie, G., Liu, K.-K., Jin, M., Chen, Y., Yang, X., Guan, Z.-J., Xing, H., & Fang, Y. (2024). Angewandte Chemie International Edition, 64(1), e202416884.

He, H.-H., Yuan, J.-P., Cai, P.-Y., Wang, K.-Y., Feng, L., Kirchon, A., Li, J., Zhang, L.-L., Zhou, H.-C., & Fang, Y. (2023). Journal of the American Chemical Society, 145, 17164–17175.

Fang, Y., Powell, J., Li, E., Wang, Q., Perry, Z., Kirchon, A., Yang, X., Xiao, Z., Zhu, C., Zhang, L., Huang, F., & Zhou, H.-C. (2019). Chemical Society Reviews, 48(17), 4707–4730.

Liang, Y., Li, E., Wang, K., Guan, Z.-J., He, H.-H., Zhang, L.-L., Zhou, H.-C., Huang, F., & Fang, Y. (2022). Chemical Society Reviews, 51, 8378–8405.

Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Published on by Biotechnology Scientist

Prof. Dr. Manish Kohli | Molecular Diagnostics | Excellence in Research Award

Director at University of Utah-Huntsman Cancer Institute | United States

Dr. Manish Kohli is a distinguished physician-scientist and academician whose career spans over two decades, focusing on transforming cancer care through convergence science and translational oncology. He currently serves as a tenured professor in the Department of Medicine at the University of Utah and holds the Jack and Hazel Robertson Presidential Endowed Chair in Cancer Research at the Huntsman Cancer Institute. Known for integrating clinical insight with computational approaches, Dr. Kohli leads multi-disciplinary research to develop personalized treatment strategies, particularly in prostate cancer. He is also the Director of the Physician Scientist Training Program, where he mentors emerging physician-researchers in internal medicine.

Profile

Scopus

Orcid

Education

Dr. Kohli received his M.B.B.S. from Maulana Azad Medical College, University of Delhi, followed by a residency in internal medicine at Cook County Hospital in Chicago. He completed his hematology and oncology fellowship training at the University of Arkansas for Medical Sciences. To enhance his skills in clinical research and data science, he pursued advanced training through certificate programs at Harvard Medical School, focusing on clinical trials and artificial intelligence in healthcare. His educational foundation reflects a seamless blend of clinical proficiency and data-driven research expertise.

Experience

Dr. Kohli has held academic and clinical leadership roles at several renowned institutions, including Mayo Clinic, H. Lee Moffitt Cancer Center, University of Rochester, and the University of Illinois at Urbana-Champaign. He served as Vice-Chair in the Department of Genitourinary Oncology and Director of Personalized Medicine at Moffitt Cancer Center. At Mayo Clinic, he was Professor of Oncology and a consultant in both medical oncology and urology. His administrative experience includes directing fellowship programs, co-chairing disease-specific working groups, serving on IRBs, and contributing to molecular pathology committees. His current role at the University of Utah includes active involvement in faculty advisory and innovation committees, shaping strategic research and training agendas.

Research interest

Dr. Kohli’s research lies at the intersection of cancer biology, bioengineering, and computational sciences. His major focus is on developing ultra-sensitive liquid biopsy technologies and fusing them with omics-based data to generate predictive biomarkers for therapy selection. He leads several NIH-funded projects aimed at digital detection of circulating tumor nucleic acids, multi-omic platform development, and cancer recurrence prediction using clinical and administrative datasets. His team utilizes machine learning algorithms to support biomarker-guided clinical trial designs and optimize therapeutic decisions. Another vital component of his research involves health economic outcomes to address disparities and costs in oncology care.

Award

Dr. Kohli has received numerous recognitions for his scientific contributions and mentorship. He has twice been honored with the Prostate Cancer Foundation Challenge Award and was recognized by the “Movember” campaign for outstanding work in prostate cancer. His teaching excellence has been acknowledged by institutions such as Mayo Clinic, and he has received awards from the VA system for clinical service. Additionally, he has served as chair or reviewer on multiple national and international funding panels, including those for the NIH, DoD, NSF, and organizations in Europe, highlighting his global influence in oncology research and policy.

Publication

Dr. Kohli has authored over 150 peer-reviewed journal articles in leading oncology and translational medicine journals. Representative publications include:

Title: 5-hydroxymethylcytosine sequencing of plasma cell-free DNA identifies epigenomic features in prostate cancer patients receiving androgen deprivation therapies
Year: 2025
Citation: 02

Title: Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer
Year: 2025

Title: Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer
Year: 2025

Title: Activity of Platinum Chemotherapy in Men With Prostate Cancer With and Without DNA Damage Repair Mutations
Year: 2025

Title: Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer
Year: 2025
Citation: 01

Title: Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer
Year: 2024
Citation: 01

Conclusion

Dr. Manish Kohli’s career embodies the synergy of clinical excellence, data science, and academic leadership. Through his ongoing work in convergence oncology, he continues to pioneer innovative diagnostics and treatment models that personalize and improve cancer care. His leadership in education, editorial roles, and multi-institutional research reflects a commitment to integrating translational science with real-world impact. With his multidisciplinary approach and focus on health equity, Dr. Kohli remains a transformative figure in advancing the future of precision oncology.